- Home
- MPAA vs ANVS Comparison
MPAA vs ANVS Comparison
Compare MPAA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPAA | ANVS |
|---|---|---|
| Founded | 1968 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.7M | 69.1M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MPAA | ANVS |
|---|---|---|
| Price | $12.14 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.50 | $13.50 |
| AVG Volume (30 Days) | 96.6K | ★ 587.3K |
| Earning Date | 06-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 162.63 | 39.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $789,806,000.00 | N/A |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.28 | N/A |
| 52 Week Low | $9.29 | $1.54 |
| 52 Week High | $18.12 | $5.50 |
Technical Indicators
Market Signals| Indicator | MPAA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 34.45 | 54.69 |
| Support Level | $12.36 | $1.73 |
| Resistance Level | $13.81 | $2.02 |
| Average True Range (ATR) | 0.72 | 0.10 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 47.67 | 72.77 |
Price Performance
Historical ComparisonAbout MPAA Motorcar Parts of America Inc.
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts, test solutions, and diagnostic equipment. Its replacement parts are mainly sold to automotive retail chain stores, warehouse distributors across North America, and automobile manufacturers for aftermarket and warranty replacement programs. The Company's test solutions and diagnostic equipment serve the automotive component and powertrain testing market. Its product portfolio includes rotating electrical products such as alternators and starters; brake-related products including brake calipers, brake rotors, brake pads, brake master cylinders, and wheel hub assemblies and bearings; and other products. Its segments are Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.